 |
|
Additive Effect of Dorzolamide on Aqueous Humor Flow in Patients Receiving Long-term Treatment With Timolol
Laura L. Wayman, MS;
Lill-Inger Larsson, MD;
Todd L. Maus, MD;
Richard F. Brubaker, MD
Arch Ophthalmol. 1998;116:1438-1440.
Objective To determine the additive effect on aqueous humor flow of short-term dorzolamide treatment in patients with glaucoma receiving long-term treatment with timolol.
Subjects and Methods Thirty-nine patients with glaucoma, 19 at Mayo Clinic, Rochester, Minn, and 20 at the University of Uppsala, Uppsala, Sweden, who had been receiving timolol treatment in both eyes for at least 1 year were studied. Aqueous flow was measured with fluorophotometry and intraocular pressure with tonometry. The effect of dorzolamide was compared with placebo when added to the long-term treatment regimen with timolol.
Results Dorzolamide reduced aqueous humor flow by 24% ± 11% (mean ± SD). The intraocular pressure as compared with placebo in the US cohort was reduced by 10% ± 6% and in the Swedish cohort by 18% ± 9%.
Conclusions Dorzolamide, a carbonic anhydrase inhibitor, has additive effects as an ocular hypotensive agent with timolol, a  -adrenergic antagonist, even though both drugs are suppressors of aqueous humor flow. Dorzolamide's effect on flow in these patients is the same as reported previously in normal subjects who are not taking a -adrenergic antagonist.
From the Mayo Medical School (Ms Wayman) and Mayo Clinic and Mayo Foundation (Drs Brubaker and Maus), Rochester, Minn; and the Department of Ophthalmology, Uppsala University, Uppsala, Sweden (Dr Larsson).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Dorzolamide, Alone and in Combination
Tsukamoto and Larsson
Arch Ophthalmol 2004;122:190-193.
ABSTRACT
| FULL TEXT
|
